The Glass Wall: Gendered authorship disparities in CD 19 and BCMA CAR-T Clinical Trials for lymphoma and myeloma

Aroog Khaliq,William Wesson,Emerson Logan,Carine Tabak,Muhammad Umair Mushtaq,Tara Lin,Joaquina Baranda,Leyla Shune,Al-Ola Abdallah,Joseph McGuirk,Mehdi Hamadani,Nausheen Ahmed

DOI: https://doi.org/10.1016/j.clml.2024.05.022

2024-06-03

Abstract:Existing literature suggests that women are significantly underrepresented in the field of hematology-oncology. Women make up 35.6% of hematologists and data on females as site investigators for pivotal trials and authors in publications of pivotal trials in hematologic malignancies, specifically in the novel niche of Chimeric antigen receptor T cell (CAR-T), is sparse. We examined the proportion of women in pivotal trials, screening a total of 2180 studies from PubMed using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. 2180 initially searched records were filtered by date (2017-2023) and clinical trial status, yielding 149 records. Following a manual review, we included 15 studies that led to the approval of or anticipated approval of CD19 and BCMA CAR-T therapies in lymphoid and plasma cell malignancies. We examined overall number of female authors, number of lead female authors, and ratio of all authors to female authors in the 15 trials, which were all high impact, cited on average 1314 times. Of the 436 authors assessed, 132 were female, correlating to 29.5% female authorship. The only study with female authorship >50% was ELIANA, a 2017 pediatric study. 7 of the 15 studies had female lead authors; notably, 6 out of 7 of these studies were published in 2021 or later. In conclusion, our data suggests gender iniquities for female investigators exist in the field of immune effector cell therapy. We suggest further investigation and strategies to decrease gendered authorship disparities. Micro Existing studies suggest women are underrepresented in hematologic research authorship in lymphoma and myeloma broadly. We assessed 15 pivotal Chimeric antigen receptor T cell (CAR-T) trials to determine the extent of gender disparity in authorship in this niche. Of the 436 authors assessed, 132 were female, correlating to 29.5% female authorship. Thus, even in CAR-T spaces, there is a need for gender equity.

oncology,hematology